US Stock MarketDetailed Quotes
GLTO Galecto
- 5.240
- +0.055+1.06%
Close Dec 17 16:00 ET
- 5.240
- 0.0000.00%
Post 18:27 ET
6.90MMarket Cap-0.27P/E (TTM)
5.320High4.850Low18.37KVolume5.180Open5.185Pre Close94.19KTurnover1.51%Turnover RatioLossP/E (Static)1.32MShares23.50052wk High0.33P/B6.36MFloat Cap4.85052wk Low--Dividend TTM1.21MShs Float449.750Historical High--Div YieldTTM9.07%Amplitude4.850Historical Low5.127Avg Price1Lot Size
Heat List
US
Overall
Symbol
Price
% Chg
No Data
Galecto Stock Forum
Galecto Completes Strategic Review to Focus on Oncology and Liver Disease and Acquires Acute Myeloid Leukemia Preclinical Asset from Bridge Medicines
• Galecto will focus on cancer and liver disease, leveraging existing clinical stage asset GB1211
• Bolsters pipeline by obtaining global rights to BRM-1420, a novel dual ENL-YEATS and FLT3 inhibitor for multiple genetic subsets of acute myeloid leukemia (AML)
• BRM-1420 has the potential for enhanced clinical effectivenes...
NEWS
Galecto Announces First Patient Dosed in an Investigator-Initiated Phase 2 Trial of GB1211 in Combination with Pembrolizumab
Galecto, Inc. announced the enrollment of the first patient in an investigator-initiated Phase 2 trial to evaluate GB1211, a galectin-3 inhibitor, in combination with pembrolizumab for metastatic melanoma and head and neck squamous cell carcinoma. Galecto aims to explore GB1211's potential to enhance the effectiveness of pembrolizumab in various can...
@FiReBiTriXiE @jimmy the trader @MangoXXX @PYUN970IHaveChosen @Ripper @Rivera @Trytosaveabit @VinylEagle @Wind_Storm @8 Seconds
Topline Results from MYLOX-1 Trial Demonstrate Reduction in Fibrosis of the Bone Marrow in Patients with Myelofibrosis
AH volume 1.2M and growing
positive trial data 👍
2 MINUTES AGO, 4:05 PM EST
VIA GLOBENEWSWIRE
No comment yet